Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
November 11, 2020 20:00 ET
|
Bragar Eagel & Squire
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Celsion Corporation to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on Monday, November 16, 2020
November 09, 2020 08:30 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the third...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zosano Pharma, Celsion, Citigroup, and Raytheon and Encourages Investors to Contact the Firm
November 04, 2020 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Moore Kuehn, PLLC Encourages Investors of CLSN, PGEN or TCMD to Contact Law Firm
November 03, 2020 12:57 ET
|
Moore Kuehn
NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible...
Celsion Corporation Issues Letter to Stockholders
October 12, 2020 08:00 ET
|
Celsion CORP
CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox® Investigator-Sponsored Studies LAWRENCEVILLE, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study
September 08, 2020 08:35 ET
|
Celsion CORP
Agreement Includes 1 Million Shares Purchased at 28% Market Premium LAWRENCEVILLE, N.J, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company,...
Celsion Corporation Restructures its Strategic Loan Facility
September 02, 2020 08:00 ET
|
Celsion CORP
Completes New $5 Million Loan Agreement with Market Competitive Terms and Debt Reduction Consistent with Celsion’s Capitalization New Agreement Ensures A Strong Balance Sheet and Additional...
Celsion Corporation Reports Second Quarter 2020 Financial Results and Provides Business Update
August 14, 2020 08:00 ET
|
Celsion CORP
Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Will Continue Following Patients in Phase III OPTIMA Study for Overall Survival;Data Maturity at Issue Conference Call...
Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer
July 27, 2020 08:30 ET
|
Celsion CORP
Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients Non-Viral Nanoparticle Delivery System, TheraPlas Platform, Demonstrates Potential for...
Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time
July 14, 2020 08:30 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its...